| Abstrak/Abstract |
Mycophenolic acid (MPA) is an immunosuppressant with a narrow therapeutic window and shows extensive interindividual and intraindividual pharmacokinetic variations that may lead to the risk of graft rejection or treatment failure, infection risk and toxicities. These inter-individual differences are partly attributed to genetic factors. Previous studies demonstrated that genetic variations in UGT1A9, UGT1A8, UGT2B7 and SLCO1B1 have been shown to be associated with response to mycophenolic acid. However, these studies have been predominantly done in Caucasian populations and limited to Asian populations (mainly Chinese and Japanese). There is still very few reports on the pharmacogenomics of MPA in the Malaysian and Indonesian population.
The main objectives of this study are to investigate the impact of patient genetic factors, specially the genetic polymorphism of the UGT1A9 gene, and clinical factors on mycophenolic acid pharmacokinetics (PK). Patients who receive mycophenolic acid in all forms will be recruited for this study. Blood samples will be collected from the patients for genotyping analysis and measurement of MPA levels in the blood.
With this project, it addresses the current research gaps where there are limited studies on Therapeutic Drug Monitoring (TDM) and the pharmacogenomic of MPA among Asian populations and the impact of genetic variants on the MPA pharmacokinetics in the Asian population. This project will introduce novel findings to identify the identification of patient genetic polymorphisms of MPA and their impacts, which is crucial in optimizing the dose of MPA.
|
